NCT07137585View on ClinicalTrials.gov

A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 16, 2026

Study Completion Date

March 3, 2027

Conditions
Type 2 Diabetes MellitusObesityOverweight
Interventions
DRUG

Placebo

RO7204239 matching placebo will be administered as per the schedule specified in the treatment arm.

DRUG

RO7204239

RO7204239 will be administered as per the schedule specified in the treatment arm.

Trial Locations (1)

D-41460

RECRUITING

Profil Institut für Stoffwechselforschung, Neuss

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY